Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ulipristal acetate (CDB-2914) 是一种具有抗孕酮活性的选择性孕酮受体调节剂。它可抑制子宫平滑肌瘤病的生长。它通过抑制或延迟排卵和影响子宫内膜组织,可用作紧急避孕药。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 454 | 现货 | ||
10 mg | ¥ 649 | 现货 | ||
50 mg | ¥ 1,591 | 现货 | ||
100 mg | ¥ 2,431 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 454 | 现货 |
产品描述 | Ulipristal acetate (CDB-2914) is an orally bioavailable, acetate salt of ulipristal, a selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system. As a result, this agent may suppress the growth of uterine leiomyomatosis. Furthermore, by inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception. |
体外活性 | Ulipristal acetate blocks activin A modulation of fibronectin and vascular endothelial growth factor A (VEGF-A) mRNA expression in cultured myometrial and leiomyoma cells[2]. Ulipristal acetate decreases the DNA fragmentation at the 100-ng/mL dose and continuing up to the 10,000-ng/mL dose compared to those spermatozoa in the control group[3]. |
体内活性 | Ulipristal and CDB-4124 have significant antiprogestational activity in vivo[1]. Ulipristal acetate decreases incidences of fibroadenomas and adenocarcinomas in the mammary gland in all treated groups. Ulipristal acetate exposure [AUC(0-24h)] at the highest dose in rats is 67 times human therapeutic exposure at 10 mg/day. In mice, there is no increase in tumors of any type at Ulipristal acetate exposures up to 313 times therapeutic exposure. Ulipristal acetate-related findings in mice are limited to organ weight changes in the liver, pituitary, thyroid/parathyroid glands, and epididymis as well as minimal panlobular hepatocellular hypertrophy in male and female mice receiving 130 mg/kg/day[4]. Ulipristal acetate (1 mg/kg and 5 mg/kg) increases the frequency with which pathologists assessed the endometrium as being thickened compared to controls in a dose-dependent manner. There is a slight decrease in secretory differentiation with increasing dose of Ulipristal acetate, with small decreases in frequency of sub- and supra-nuclear vacuolation[5]. |
别名 | Ulipristal, 醋酸乌利司他, CDB-2914 |
分子量 | 475.62 |
分子式 | C30H37NO4 |
CAS No. | 126784-99-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (105.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1025 mL | 10.5126 mL | 21.0252 mL | 52.563 mL |
5 mM | 0.4205 mL | 2.1025 mL | 4.205 mL | 10.5126 mL | |
10 mM | 0.2103 mL | 1.0513 mL | 2.1025 mL | 5.2563 mL | |
20 mM | 0.1051 mL | 0.5256 mL | 1.0513 mL | 2.6281 mL | |
50 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL | |
100 mM | 0.021 mL | 0.1051 mL | 0.2103 mL | 0.5256 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ulipristal acetate 126784-99-4 Autophagy Endocrinology/Hormones Others Estrogen/progestogen Receptor Progesterone Receptor NR3C3 inhibit CDB2914 Ulipristal Acetate anti-fertility anti-glucocorticoid CDB 2914 Inhibitor anti-progestational Ulipristal contraception leiomyoma 醋酸乌利司他 uterine CDB-2914 emergency inhibitor